Our Technoligies

Lanthipeptides are more stable
than linear wild-type peptides and therefore
have much better "drug-like" properties

LantioPharma a Morphosys company

In May2015, MorphoSys
acquired LantioPharma

Welcome to Lanthio Pharma

Lanthio Pharma is a Dutch biopharmaceutical company committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity.

Utilizing our technology we are building a growing pipeline of stabilized, receptor-specific lanthipeptides with the potential for treatment of fibrosis, heart failure and multiple sclerosis.

Lanthio’s lead product, MOR107 (formerly LP2), is a selective AT2 receptor agonist, in development for Diabetic Nephropathy, with possible further applications in IPF and other fibrotic diseases.

MOR107 is currently in preclinical development.

On May 7th, 2015 MorphoSys AG announced that it has acquired all outstanding shares of Lanthio Pharma BV

Lanthio Pharma and MorphoSys scientists publish lanthipeptide phage...
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide...
MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical...
Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed...
MorphoSys Acquires Lanthio Pharma
Lanthio Pharma Receives Gouden KIEM Award as Dutch Chemical Start-up of...
MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
Lanthio Pharma announces change of CEO
Lanthio Pharma receives Dutch Government loan of up to €3.6 million to...
Lanthio Pharma receives European Grant